Clinical Trial Update: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) [Phase 3]

View source ↗

Summary

Phase 3 TOPAZ-1 trial results for durvalumab in combination with gemcitabine/cisplatin in first-line biliary tract cancer have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: AstraZeneca | Conditions: Biliary Tract Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-04-13